Abstract
In 1956, (±)-thalidomide was introduced into the market in Europe as sedative and drug for morning sleeping sickness which resulted into a tragedy called thalidomide tragedy (softenon drama) due to its teratogenic effects in newly born babies. Thalidomide was banned all over the world due to this havoc, which was a big breakdown in the history of this drug. But, in 1998 it resurged after US, FDA approved it for treating Erythema Leprosum Nodosum (ENL). Besides, recently thalidomide and its derivatives showed remarkable property for controlling several malignancies. Thalidomide and its analogues have been used for treating metastatic prostate cancer, multiple myeloma, HIV-related ulcers, Kaposi's sarcoma, weight loss and body wasting associated with HIV. The present article describes the sate-of-art of thalidomide applications with special emphasis on pharmacology, pharmacokinetics, breakdown in the history, break through and resurgence, potential future anticancer drug, potencies of thalidomide vs its analogues, mechanism of anticancer action, different stages and toxicity management. Besides, efforts were also made to predict the future perspectives of thalidomide and its analogues.
Keywords: Anticancer drugs, break down and resurgence, future perspectives, mechanism of action, thalidomide, thalidomide analogues
Current Drug Therapy
Title:Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Volume: 7 Issue: 1
Author(s): Imran Ali, Waseem A. Wani, Kishwar Saleem and Ashanul Haque
Affiliation:
Keywords: Anticancer drugs, break down and resurgence, future perspectives, mechanism of action, thalidomide, thalidomide analogues
Abstract: In 1956, (±)-thalidomide was introduced into the market in Europe as sedative and drug for morning sleeping sickness which resulted into a tragedy called thalidomide tragedy (softenon drama) due to its teratogenic effects in newly born babies. Thalidomide was banned all over the world due to this havoc, which was a big breakdown in the history of this drug. But, in 1998 it resurged after US, FDA approved it for treating Erythema Leprosum Nodosum (ENL). Besides, recently thalidomide and its derivatives showed remarkable property for controlling several malignancies. Thalidomide and its analogues have been used for treating metastatic prostate cancer, multiple myeloma, HIV-related ulcers, Kaposi's sarcoma, weight loss and body wasting associated with HIV. The present article describes the sate-of-art of thalidomide applications with special emphasis on pharmacology, pharmacokinetics, breakdown in the history, break through and resurgence, potential future anticancer drug, potencies of thalidomide vs its analogues, mechanism of anticancer action, different stages and toxicity management. Besides, efforts were also made to predict the future perspectives of thalidomide and its analogues.
Export Options
About this article
Cite this article as:
Ali Imran, A. Wani Waseem, Saleem Kishwar and Haque Ashanul, Thalidomide: A Banned Drug Resurged into Future Anticancer Drug, Current Drug Therapy 2012; 7 (1) . https://dx.doi.org/10.2174/157488512800389164
DOI https://dx.doi.org/10.2174/157488512800389164 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanosized Drug Delivery Systems for Direct Nose to Brain Targeting: A Review
Recent Patents on Drug Delivery & Formulation Isolation, Characterization and Preliminary Cytotoxic and Antifungal Evaluations of Novel Lancifoliate Isolated from Methanol Extract of <i>Conocarpus lancifolius</i>
Anti-Cancer Agents in Medicinal Chemistry Let-7a Could Serve as A Biomarker for Chemo-Responsiveness to Docetaxel in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry DNA Demethylation: Where Genetics Meets Epigenetics
Current Pharmaceutical Design Germacrone: A Potent Secondary Metabolite with Therapeutic Potential in Metabolic Diseases, Cancer and Viral Infections
Current Drug Metabolism Nerve Growth Factor Receptors and Signaling in Breast Cancer
Current Cancer Drug Targets Glioma Targeting and Anti-glioma Effect of Interleukin 13 Peptide and RGD Peptide Dual Functionalized Nanoparticles
Current Pharmaceutical Biotechnology Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Tracking Stem Cells for Cellular Therapy in Stroke
Current Pharmaceutical Design Heterodimeric Amino Acid Transporters: Molecular Biology and Pathological and Pharmacological Relevance
Current Drug Metabolism Minocycline and Doxycycline: More Than Antibiotics
Current Molecular Pharmacology PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Integrins in Drug Targeting-RGD Templates in Toxins
Current Pharmaceutical Design Fibroblast Growth Factor-2 Antagonist and Antiangiogenic Activity of Long-Pentraxin 3-Derived Synthetic Peptides
Current Pharmaceutical Design Cancer Stem Cells: How can we Target them?
Current Medicinal Chemistry Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19
Current Pharmaceutical Design Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin
Current Medicinal Chemistry Combined Chemotherapy or Biotherapy with Jasmonates: Targeting Energy Metabolism for Cancer Treatment
Current Pharmaceutical Biotechnology Iron Oxide Nanoparticle Platform for Biomedical Applications
Current Medicinal Chemistry